Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer ... 4-traders (press release) The SmPC is available at www.pixuvri.eu. CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the ... |
